Home › Funds › GSK plc › LYEL

GSK plc position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

GSK plc reported holding 1,512,659 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$14.8M, representing 2.98% of its reported portfolio and ranking #7 among its reported holdings. GSK plc has disclosed LYEL holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.51M sh
Reported value held$14.81M
Portfolio Weight2.98%
First reportedQ4 2025
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GSK plc's LYEL position evolved

GSK plc first disclosed a stake in LYEL in Q4 2025 at 1,512,659 shares (US$46.6M). Across 4 filings, GSK plc held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,512,659 shares valued at US$14.8M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.51M $46.56M New
Q1 2026 1.51M $30.34M Hold
Q2 2026 1.51M $21.25M Hold
Q3 2026 1.51M $14.81M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), Orland Properties Ltd (US$10.6M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has GSK plc held LYEL?

GSK plc has disclosed LYEL holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is GSK plc's current position in LYEL?

As of Q3 2026, GSK plc holds 1.51M shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $14.81M, representing 2.98% of its reported portfolio and ranking #7.

Has GSK plc been buying or selling LYEL?

In the latest 13F filing (Q3 2026), GSK plc held unchanged its position in LYEL.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, Orland Properties Ltd, Decheng Capital LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.